{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:36:12Z","timestamp":1773322572776,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008081","name":"Southeast University","doi-asserted-by":"publisher","award":["2024-K03"],"award-info":[{"award-number":["2024-K03"]}],"id":[{"id":"10.13039\/501100008081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20222008"],"award-info":[{"award-number":["BK20222008"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.tox.2025.154321","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T01:06:26Z","timestamp":1761354386000},"page":"154321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ceritinib\u2013ibuprofen synergistic hepatotoxicity: Insights from real-world data and liver organoid models"],"prefix":"10.1016","volume":"519","author":[{"given":"Shiyi","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xulei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuepu","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongze","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-4540","authenticated-orcid":false,"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2025.154321_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tox.2025.154321_bib2","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.7150\/ijbs.83574","article-title":"Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks","volume":"19","author":"Stravopodis","year":"2023","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.tox.2025.154321_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.critrevonc.2019.02.006","article-title":"ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer","volume":"136","author":"Rosas","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tox.2025.154321_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tox.2025.154321_bib5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tox.2025.154321_bib6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/JTO.0000000000000566","article-title":"Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors","volume":"10","author":"Nishio","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tox.2025.154321_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/toxics13030210","article-title":"Safety Profile and Hepatotoxicity of Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Disproportionality Analysis Based on FDA Adverse Event Reporting System Database","volume":"13","author":"Yang","year":"2025","journal-title":"Toxics"},{"key":"10.1016\/j.tox.2025.154321_bib8","unstructured":"Diseases, N.Io.DaDa.K., Ceritinib, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2017, National Institutes of Health: Bethesda, MD."},{"key":"10.1016\/j.tox.2025.154321_bib9","unstructured":"DrugBank, Ceritinib, in DrugBank: Comprehensive Drug Information, DrugBank, Editor. 2025, DrugBank: Calgary, Canada."},{"key":"10.1016\/j.tox.2025.154321_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2217\/pgs.13.24","article-title":"Genetic Characterization to Improve Interpretation and Clinical Management of Hepatotoxicity Caused by Tyrosine Kinase Inhibitors","volume":"14","author":"Spraggs CF","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.tox.2025.154321_bib11","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.2174\/0929867330666221209102650","article-title":"Mutual Prodrugs - Codrugs","volume":"30","author":"Nudelman","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tox.2025.154321_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102822","article-title":"Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs","volume":"145","author":"Akbulut","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tox.2025.154321_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad445","article-title":"Drug-drug interaction prediction: databases, web servers and computational models","volume":"25","author":"Zhao","year":"2023","journal-title":"Brief. Bioinform"},{"key":"10.1016\/j.tox.2025.154321_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","article-title":"Acute and clinically relevant drug-induced liver injury: a population based case-control study","volume":"58","author":"de Abajo","year":"2004","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.tox.2025.154321_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072605","article-title":"Anti-Inflammatory Drugs as Anticancer Agents","volume":"21","author":"Zappavigna","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.tox.2025.154321_bib16","series-title":"2018 Oncology nursing drug handbook","author":"Wilkes","year":"2017"},{"key":"10.1016\/j.tox.2025.154321_bib17","article-title":"Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Swarm","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.tox.2025.154321_bib18","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1039\/D2LC00307D","article-title":"Liver organ-on-chip models for toxicity studies and risk assessment","volume":"22","author":"Messelmani","year":"2022","journal-title":"Lab Chip"},{"key":"10.1016\/j.tox.2025.154321_bib19","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nat. Rev. Methods Prim."},{"key":"10.1016\/j.tox.2025.154321_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13578-023-01136-x","article-title":"Liver organoid culture methods","volume":"13","author":"Hu","year":"2023","journal-title":"Cell Biosci."},{"key":"10.1016\/j.tox.2025.154321_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105608","article-title":"Liver organoid as a 3D in vitro model for drug validation and toxicity assessment","volume":"169","author":"Brooks","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.tox.2025.154321_bib22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.tox.2025.154321_bib23","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.drudis.2019.09.002","article-title":"Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls","volume":"24","author":"Vlot","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tox.2025.154321_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100046","article-title":"Pharmacological interactions: Synergism, or not synergism, that is the question","volume":"2","author":"Calzetta","year":"2021","journal-title":"Curr. Res Pharm. Drug Discov."},{"key":"10.1016\/j.tox.2025.154321_bib25","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tox.2025.154321_bib26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/s42003-025-08205-6","article-title":"Development of an AI model for DILI-level prediction using liver organoid brightfield images","volume":"8","author":"Tan","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.tox.2025.154321_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00280-020-04180-3","article-title":"Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK\u2009+\u2009advanced tumors","volume":"87","author":"Hurtado","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.tox.2025.154321_bib28","article-title":"Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tox.2025.154321_bib29","article-title":"Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer","volume":"98","author":"Li","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.tox.2025.154321_bib30","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1073\/pnas.0913377107","article-title":"Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition","volume":"107","author":"Limongelli","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.tox.2025.154321_bib31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.redox.2016.10.001","article-title":"Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and therapeutic potential","volume":"10","author":"Du","year":"2016","journal-title":"Redox Biol."},{"key":"10.1016\/j.tox.2025.154321_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2023.1193413","article-title":"Aspects to consider in causality assessment of safety signals: broadening the thought process","volume":"3","author":"Hammad","year":"2023","journal-title":"Front Drug Saf. Regul."},{"key":"10.1016\/j.tox.2025.154321_bib33","unstructured":"Agency, E.M. Signal management. 2025 26 September 2025]; Available from: \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/signal-management\u3009."},{"key":"10.1016\/j.tox.2025.154321_bib34","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tox.2025.154321_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10787-009-0016-x","article-title":"Ibuprofen: pharmacology, efficacy and safety","volume":"17","author":"Rainsford","year":"2009","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.tox.2025.154321_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.580289","article-title":"Analgesic Effect of Acetaminophen: A Review of Known and Novel Mechanisms of Action","volume":"11","author":"Ohashi","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.tox.2025.154321_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1503\/cmaj.1040752","article-title":"Liver enzyme alteration: a guide for clinicians","volume":"172","author":"Giannini","year":"2005","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.tox.2025.154321_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jat.834","article-title":"Influence of water extracts from the surface of two Yew (Taxus) species on mites (Tetranychus urticae)","volume":"22","author":"Furmanowa","year":"2002","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.tox.2025.154321_bib39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/bs.apha.2019.01.007","article-title":"Acetaminophen hepatotoxicity: A mitochondrial perspective","volume":"85","author":"Ramachandran","year":"2019","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.tox.2025.154321_bib40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/03602532.2011.602688","article-title":"Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity","volume":"44","author":"Jaeschke","year":"2012","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.tox.2025.154321_bib41","first-page":"1767","article-title":"The co-drug strategy for metabolic diseases and comorbidity management: a comprehensive review","volume":"24","author":"Nayak","year":"2024","journal-title":"Biochem. amp Cell. Arch."},{"key":"10.1016\/j.tox.2025.154321_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s13318-023-00826-8","article-title":"Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions","volume":"48","author":"Lim","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.tox.2025.154321_bib43","unstructured":"Hussain, A., Validation of novel HPLC methods to analyse metabolic reaction products catalysed by CYP450 enzymes and in vitro measurement of Drug-Drug Interactions. 2022, Kingston University."},{"key":"10.1016\/j.tox.2025.154321_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.toxlet.2015.01.013","article-title":"Chrysin, baicalein and galangin are indirect activators of the human constitutive androstane receptor (CAR)","volume":"233","author":"Carazo Fern\u00e1ndez","year":"2015","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.tox.2025.154321_bib45","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1053\/j.gastro.2020.10.002","article-title":"High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids","volume":"160","author":"Shinozawa","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tox.2025.154321_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116653","article-title":"Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism","volume":"475","author":"Yuan","year":"2023","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.tox.2025.154321_bib47","unstructured":"Administration, U.S.Fa.D., Clinical Pharmacology and Biopharmaceutics Review(s) NDA 205755. 2014: Silver Spring, MD."},{"key":"10.1016\/j.tox.2025.154321_bib48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jsb.2007.12.004","article-title":"A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography","volume":"162","author":"Zhu","year":"2008","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.tox.2025.154321_bib49","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/0929866529666220426124834","article-title":"Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review","volume":"29","author":"Molaei","year":"2022","journal-title":"Protein Pept. Lett."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X2500280X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X2500280X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:09:41Z","timestamp":1773263381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X2500280X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"alternative-id":["S0300483X2500280X"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2025.154321","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceritinib\u2013ibuprofen synergistic hepatotoxicity: Insights from real-world data and liver organoid models","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2025.154321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154321"}}